TYRP1 and neoplasm: In addition, this analysis suggested that a CD3 bi-specific antibody may not be the optimal therapeutic modality due to relatively low expression levels of the underlying genes in the tumor microenvironment, but other options such as TYRP1 CAR-therapy may prove viable (36).